Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record RevenueGlobeNewsWire • 02/26/26
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026GlobeNewsWire • 02/19/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGOGlobeNewsWire • 02/03/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGOPRNewsWire • 01/29/26
Organogenesis Announces Initiation of Biologics License Application for ReNu®GlobeNewsWire • 12/23/25
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 GuidanceGlobeNewsWire • 11/06/25
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/31/25
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGOBusiness Wire • 10/17/25
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025GlobeNewsWire • 10/01/25
Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain BullishSeeking Alpha • 09/29/25
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/27/25
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025GlobeNewsWire • 07/22/25
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued InnovationGlobeNewsWire • 07/15/25